NRX Pharmaceuticals (NRXP) FCF Margin (2025 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly FCF Margin of 402.62% for Q1 2026, down 4.22% quarter-over-quarter from 386.33% in Q4 2025.

NRX Pharmaceuticals (NRXP) FCF Margin (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported FCF Margin for 2 consecutive years, with 402.62% the latest figure, recorded in Q1 2026.

In Q1 2026, FCF Margin changed N/A year-over-year to 402.62%; the TTM figure through Mar 2026 stood at 670.26% (changed N/A YoY), while the FY2025 annual figure was 1175.0%, changed N/A from the prior year.
FCF Margin fell to 402.62% in Q1 2026 per NRXP's latest filing, from 386.33% in the prior quarter.
Across five years, FCF Margin topped out at 386.33% in Q4 2025 and bottomed at 1445.5% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	13.35%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	41.07%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	70.82%
10	NRX Pharmaceuticals	132.53 Mn	105.83 Mn	426,000.00	-808.36%

Download Data